Preparation and characterization of a fully human monoclonal antibody specific for human tumor necrosis factor alpha
Open Access
- 9 December 2021
- journal article
- research article
- Published by Taylor & Francis in Bioengineered
- Vol. 12 (2) , 10821-10834
Abstract
Tumor necrosis factor alpha (TNFα) is an important inflammatory factor. It plays a cardinal role in inflammatory synovitis and articular matrix degradation, and is, therefore, a prime target for directed immunotherapy in autoimmune diseases. In this study, we screened and isolated the B cells secreting anti-TNFα antibody from patients with rheumatoid arthritis. The heavy-chain and light-chain sequences of the antibody were cloned and used to generate a stable Chinese hamster ovary (CHO) cell line producing the antibody, which was named Haidalimumab. Haidalimumab showed a TNFα binding affinity comparable to that of the antibody Humira, which is the best TNF inhibitor on the market. Furthermore, Haidalimumab could effectively neutralize recombinant human tumor necrosis factor alpha (rhTNFα) toxicity in a C57BL/6 mouse model and showed significant therapeutic effect in a tumor necrosis factor transgenic (TNF-Tg) mouse arthritis model. In conclusion, we developed a high-affinity, fully human anti-TNFα antibody with low immunogenicity that could potentially have significant therapeutic applications in rheumatoid arthritis or other autoimmune diseases. Abbreviations: ELISAenzyme linked immunosorbent assayRArheumatoid arthritisSDS-PAGEsodium dodecyl sulfate polyacrylamide gel electrophoresisrhTNFαrecombinant human tumor necrosis factor-alphaEC50concentration for 50% of maximal effectTNF-Tg micetumor necrosis factor transgenic miceAMDactinomycin DMTTmethylthiazolyldiphenyl-tetrazolium bromidePBSphosphate‐buffered saline Graphical abstractKeywords
Funding Information
- National Key Research and Development Program of China
- Natural Science Foundation of Jiangsu
- National Natural Science Foundation of China (81903169)
- Natural Science Foundation of Jiangsu Province (BK20191175)
- Shanghai Sailing Program (19YF1422300)
- National Natural Science Foundation of China (82072767, 81770145)
This publication has 41 references indexed in Scilit:
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritisNature Reviews Rheumatology, 2013
- AdalimumabDrugs, 2012
- The Growth Factor Progranulin Binds to TNF Receptors and Is Therapeutic Against Inflammatory Arthritis in MiceScience, 2011
- Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty‐eight–week efficacy and safety results of a phase III randomized, double‐blind, placebo‐controlled studyArthritis & Rheumatism, 2010
- GolimumabBioDrugs, 2009
- Cytochrome P4502E1 sensitizes to tumor necrosis factor alpha–induced liver injury through activation of mitogen-activated protein kinases in miceHepatology, 2008
- Characterization of a novel anti-human TNF-α murine monoclonal antibody with high binding affinity and neutralizing activityExperimental & Molecular Medicine, 2008
- Characterization of lower molecular weight artifact bands of recombinant monoclonal IgG1 antibodies on non-reducing SDS-PAGEBiotechnology Letters, 2007
- A transient expression vector for recombinant protein production in Chinese hamster ovary cellsJournal of Chemical Technology & Biotechnology, 2005
- EtanerceptDrugs, 1999